Participated · Seed · Mar 2026

Laigo Bio is developing the SureTACs platform to generate bispecific antibodies that selectively degrade disease-causing membrane proteins by pairing an E3 ligase with a target protein to trigger ubiquitination and lysosomal degradation. The approach is intended to enable highly selective elimination of disease-driving membrane targets and to produce first-in-class, dual-targeted therapies. Laigo is focusing its programs on oncology as well as autoimmune and immunology indications, including graft rejection, and is advancing multiple candidate programs. The company reports in vivo and in vitro efficacy with a claimed high degree of selectivity and improved toxicity and safety. Laigo is advancing its oncology pipeline toward clinical development and progressing three autoimmune/immunology programs with support from its recent seed financing.

Participated · Series A · Apr 2024

Flindr Therapeutics is a pre-clinical precision oncology therapeutics company developing targeted cancer drugs using its ImmunoGram Drug Discovery Engine. The ImmunoGram engine reverse-translates clinical heterogeneity in tumor- and host-specific factors into lab-based biological models to screen and select key drug targets. Its lead program is a first-in-class small-molecule inhibitor of RNF31 (HOIP) that has shown promising preclinical activity in ovarian cancer and B-cell lymphoma models and for which biomarkers have been identified to aid patient selection. The company was spun out of the Netherlands Cancer Institute and the Oncode Institute in 2020 and was previously called Immagene; it is led by CEO Maarten Ligtenberg. Flindr raised €20M in a Series A financing to advance its programs. The company intends to use the funds to progress the lead program toward IND, develop a second program, and broaden its pipeline using the ImmunoGram Drug Discovery Engine.